One such agent, amivantamab, is a fully human anti-EGFR and c-MET-targeting antibody that demonstrated a 36% objective response rate and 10 month median response duration in patients with non-small cell lung cancers (NSCLC) harboring EGFR exon 20 insertions (62). The gene discussed is MET; the disease is non-small cell lung carcinoma.